期刊文献+

依立雄胺对雄激素非依赖前列腺癌细胞DU-145的作用

Effects of epristeride on human prostate carcinoma cell Line DU-145
下载PDF
导出
摘要 目的为研究依立雄胺治疗前列腺癌的可能性及可能机制,探讨依立雄胺体外对人激素非依赖型前列腺癌细胞(DU-145)生长的作用。方法用2.5,5,10,20和40μM的依立雄胺作用DU-145细胞3天后,用普通倒置显微镜进行细胞形态学观察;用黄酰罗丹明B法(SRB法)评价依立雄胺对前列腺癌细胞株DU-145的体外增殖抑制作用绘制的生长曲线;应用流式细胞仪评价依立雄胺对对前列腺癌细胞株DU-145的周期阻滞作用。结果 40μM和20μM的依立雄胺作用DU-145细胞3d后,可使其明显的皱缩凋亡;依立雄胺对DU-145呈现明显的浓度依赖的体外增殖抑制作用;通过流式细胞仪分析发现,依立雄胺对DU-145呈现明显的浓度依赖的周期阻滞作用。 Objective To study the possibility and potential mechanisms of epristeride treatment of prostate cancer,and to investigate the effect of epristeride on the growth of DU-145 cells in vitro.Method We used different concentration of epristeride (2.5,5,10,20,40mM) to interfere DU145 cells and used an inverted microscope to observe the cell morphology.We used Sulforhodamine B(SRB) to evaluate the growth curve characterized by the inhibition of in vitro proliferation of DU145 cells caused by epristeride.We applied flow cytometry to evaluate cell cycle arrest of DU145 induced by epristeride.Results An obvious cell shrinkage and apoptosis was observed three days after the interference of epristeride with the concentration of 40mM and 20mM.Epristeride shows a conspicuously concentration-dependent inhibition of in vitro proliferation of DU145 cells.Through flow cytometry,we found that epristeride demonstrated a highly Concentration dependent effect of causing cell cycle arrest in DU145 cell line.
出处 《外科研究与新技术》 2012年第2期135-138,共4页 Surgical Research and New Technique
关键词 依立雄胺 凋亡 增殖 黄酰罗丹明B法(SRB法) 细胞株 DU-145 前列腺癌 Epristeride Apoptosis Cell proliferation Sulforhodamine B Cell line DU145 Prostate cancer
  • 相关文献

参考文献13

二级参考文献71

  • 1吕坚伟,周立新,冷静,黄翼然,唐涌志,汤海,闵志廉,高轶.萘哌地尔与盐酸特拉唑嗪治疗良性前列腺增生的疗效与安全性评估[J].中国男科学杂志,2005,19(5):36-39. 被引量:20
  • 2况刚,邹文俊,高小平.一种非同位素5α-还原酶抑制剂体外筛选模型的建立和应用[J].中药药理与临床,2005,21(4):61-64. 被引量:9
  • 3王建龙,朱刚,万奔.爱普列特在治疗良性前列腺增生中的应用[J].现代泌尿外科杂志,2006,11(4):246-248. 被引量:9
  • 4项永兵,金凡,陈浩泉,周淑贞,陶蓉芳,程爱清,方茹蓉,孙璐,高立峰,高玉堂.上海市区1988年─1991年肿瘤患者生存率分析[J].中国肿瘤,1996,5(11):6-8. 被引量:24
  • 5[3]Surveillance,Epidemiology, and End Results (SEER) Program( www.seer.cancer.gov) SEER* Stat Database: Incidence-SEER 9 Regs Public-Use, Nov 2002 Sub (1973-2000), National Cancer Institute, DCCPS,Surveillance Research Program, Cancer Statistics Branch, released April 2003, based on the November 2002 submission.
  • 6[5]Kenneth JP,Jo A J,Peggy SE. Epidemiology of prostate cancer:molecular and environmental clues. Urology.1996,48 (5):676-683.
  • 7[7]Gaxiano JM, Hennekens CH.Dietary fat and risk of prostate cancer(editorial).The Journal of National Cancer Institute,1995,87(19):1427-1428.
  • 8[8]Giovannucci E.Epidemiologic characteristics of prostate cancer.Cancer,1995,75(9):1766-1777.
  • 9[10]Hsing AW,Jie D, Sesterhenn IA,et al.Body size and prostate cancer:a population-based case-control study in China. Cancer Epidemiology,Biomarkers and Prevention, 2000, 9:1335-1341.
  • 10[2]Parkin DM, Whelan SL,Ferlay J, et al.Cancer incidence in five continents.Vol.Ⅶ.IARC.Sci.Publ,143,1997.

共引文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部